186 related articles for article (PubMed ID: 35884498)
1. A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer.
Muralikrishnan V; Fang F; Given TC; Podicheti R; Chtcherbinine M; Metcalfe TX; Sriramkumar S; O'Hagan HM; Hurley TD; Nephew KP
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884498
[TBL] [Abstract][Full Text] [Related]
2. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
Wang Y; Zong X; Mitra S; Mitra AK; Matei D; Nephew KP
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518684
[TBL] [Abstract][Full Text] [Related]
3. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
4. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
5. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
6. Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.
Atwani R; Rogers A; Nagare R; Prasad M; Lazar V; Sandusky G; Pin F; Condello S
Res Sq; 2024 Mar; ():. PubMed ID: 38559125
[TBL] [Abstract][Full Text] [Related]
7. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
8. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
9. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
Kim D; Choi BH; Ryoo IG; Kwak MK
Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
[TBL] [Abstract][Full Text] [Related]
10. A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer.
Nwani NG; Condello S; Wang Y; Swetzig WM; Barber E; Hurley T; Matei D
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30965686
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M
Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528
[TBL] [Abstract][Full Text] [Related]
13. EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis.
Wang K; Wang Y; Wang Y; Liu S; Wang C; Zhang S; Zhang T; Yang X
Stem Cell Res Ther; 2021 Mar; 12(1):186. PubMed ID: 33726845
[TBL] [Abstract][Full Text] [Related]
14. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
15. HOTAIR maintains the stemness of ovarian cancer stem cells via the miR-206/TBX3 axis.
Zhang Y; Guo J; Cai E; Cai J; Wen Y; Lu S; Li X; Han Q; Jiang J; Li T; Wang Z
Exp Cell Res; 2020 Oct; 395(2):112218. PubMed ID: 32771526
[TBL] [Abstract][Full Text] [Related]
16. Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation.
Wang W; Fang F; Ozes A; Nephew KP
Mol Cancer Ther; 2021 Jun; 20(6):1092-1101. PubMed ID: 33785648
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targeting of ovarian cancer stem cells.
Wang Y; Cardenas H; Fang F; Condello S; Taverna P; Segar M; Liu Y; Nephew KP; Matei D
Cancer Res; 2014 Sep; 74(17):4922-36. PubMed ID: 25035395
[TBL] [Abstract][Full Text] [Related]
18. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
Yokoyama Y; Zhu H; Lee JH; Kossenkov AV; Wu SY; Wickramasinghe JM; Yin X; Palozola KC; Gardini A; Showe LC; Zaret KS; Liu Q; Speicher D; Conejo-Garcia JR; Bradner JE; Zhang Z; Sood AK; Ordog T; Bitler BG; Zhang R
Cancer Res; 2016 Nov; 76(21):6320-6330. PubMed ID: 27803105
[TBL] [Abstract][Full Text] [Related]
19. Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells.
Uddin MH; Kim B; Cho U; Azmi AS; Song YS
Heliyon; 2020 Nov; 6(11):e05442. PubMed ID: 33241139
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression.
Namekawa T; Ikeda K; Horie-Inoue K; Suzuki T; Okamoto K; Ichikawa T; Yano A; Kawakami S; Inoue S
Int J Cancer; 2020 Feb; 146(4):1099-1113. PubMed ID: 31187490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
